Practice Areas Corporate Governance and Compliance
Share This

Corporate Governance and Compliance

Corporate governance and compliance continues to be an evolving, much-debated and increasingly regulated area in Ireland.  The enactment of the Companies Act, 2014 has changed the regulatory landscape again, requiring Irish companies to take on board new governance and compliance obligations with effect from mid-2015. 

Our Corporate Governance and Compliance team has extensive experience in advising boards of directors, shareholders and other key stakeholders of listed and unlisted, public and private companies, financial institutions and public sector organisations on their compliance obligations under a range of regulatory regimes.  We also frequently advise in relation to shareholder and boardroom disputes.   

We work closely with our clients in designing, implementing and reviewing the effectiveness of corporate governance structures, frameworks and procedures with a view to ensuring compliance with regulatory requirements and best practice guidelines, including in relation to board structure, transparency, disclosure, engagement with stakeholders, accountability and corporate responsibility. 

Our Corporate Governance and Compliance Group advises on compliance with: 

  • UK Corporate Governance Code
  • Disclosure, Market Abuse and Transparency Regulations
  • Stock Exchange Rules and Codes of Practice on listing, disclosure, market abuse, transparency  
  • Central Bank Corporate Governance Codes 
  • Obligations under Irish companies legislation, including Directors’ Duties and Shareholder Rights 
  • Code of Practice for the Governance of State Bodies 
  • Various sector-specific regulatory regimes, including financial services, insurance, life sciences, pharmaceutical and healthcare, telecommunications, energy and waste and food and drink. 

Our Corporate Governance and Compliance Group is complemented by the ByrneWallace Corporate Secretarial, which provides the full spectrum of company secretarial services for a large number of our clients, in addition to the ByrneWallace Financial Regulatory Group who provide expertise in the event of external regulatory investigations or legal proceedings.  

Please click here for our recent publications on the regulatory changes introduced by the Companies Act, 2014

THE TEAM      
Gerry Beausang +353 1 691 5866 +353 1 691 5010
Feargal Brennan +353 1 691 5276 +353 1 691 5010
Darren Daly +353 1 691 5274 +353 1 691 5010
Neil Keenan +353 1 691 5287 +353 1 691 5010
William Kingston +353 1 691 5449 +353 1 691 5010
Eileen O'Connor +353 1 691 5300 +353 1 691 5010
Colin Sainsbury +353 1 691 5277 +353 1 691 5010
The team at ByrneWallace ‘always provides very detailed analysis’, and is notable for its cutting-edge medica... Legal 500 2014 - Corporate and Commercial view all related testimonials
The team is extremely commercial and great at pushing the deal through." "It offers excellent service and quality... Chambers Europe 2014 - Corporate view all related testimonials
ByrneWallace advises both foreign and domestic clients on the full range of corporate matters. The team is partic... Chambers Europe 2013 - Corporate view all related testimonials
ByrneWallace acted for Azur Pharm on its merger with US life sciences company Jazz Pharmaceuticals, which was a n... Legal 500 2013 - Corporate view all related testimonials
...a forward-thinking firm, as illustrated by its establishment of a new green economy group to serve clients in ... Chambers Global 2010 - Corporate view all related testimonials
ByrneWallace has ‘highly responsive and pragmatic partners’ and a particular niche in pharmaceutical and heal... Legal 500 2010 - Corporate view all related testimonials
  • Amryt Pharmaceuticals

    Acted for Amryt Pharmaceuticals Designated Activity Company (Amryt DAC) on the reverse takeover of Fastnet Equity plc

  • Zalando

    Advised Zalando on the establishment of it Irish tech operations

  • Nexvet Biopharma plc

    Acted for Nexvet Biopharma plc in relation to its fully underwritten US$40m IPO

view all related recent work
Companies Act 2014